Entropy Neurodynamics

Entropy Neurodynamics Interest Expense

The Interest Expense of Entropy Neurodynamics (ENP.AX) as of Nov 4, 2026 is -51,000.00 AUD. In the previous year, Interest Expense was -543,200.00 AUD — a change of -90.61% (higher).

Interest Expense

-51,000.00AUD

YoY

-90.61%

Last updated:

Interest Expense of Entropy Neurodynamics is 2025 -51,000.00 AUD. Interest Expense of Entropy Neurodynamics was 2024 -543,200.00 AUD. It decreases by -90.61% higher compared to the previous year.

The Entropy Neurodynamics Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2022
-81,200.00 AUD
Jan 1, 2023
-331,200.00 AUD
Jan 1, 2024
-543,200.00 AUD
Jan 1, 2025
-51,000.00 AUD
The Entropy Neurodynamics Interest Expense history
YEARInterest ExpenseYoY
-51,000.00AUD-90.61%
-543,200.00AUD+64.01%
-331,200.00AUD+307.88%
-81,200.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Entropy Neurodynamics Stock analysis

What does Entropy Neurodynamics do? Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners. Entropy Neurodynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entropy Neurodynamics stock

Interest Expense of Entropy Neurodynamics is -51,000.00 AUD in 2025.

Interest Expense of Entropy Neurodynamics changed from -543,200.00 AUD to -51,000.00 AUD, representing a -90.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense Entropy Neurodynamics since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Entropy Neurodynamics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Entropy Neurodynamics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Entropy Neurodynamics